Kingsoft (KSFTF) Receives a Buy from Jefferies
Jefferies analyst Thomas Chong maintained a Buy rating on Kingsoft (KSFTF – Research Report) on May 29 and set a price target of HK$42.80.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Chong covers the Communication Services sector, focusing on stocks such as Tencent Holdings , Kingsoft, and Weibo. According to TipRanks, Chong has an average return of 8.7% and a 50.10% success rate on recommended stocks.
In a report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a HK$45.00 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Online broker Tiger to double Hong Kong headcount, targets offshore China wealth
By Selena Li HONG KONG (Reuters) -Tiger Securities plans to double its headcount in Hong Kong over the next two to three years as the online brokerage targets a bigger share of the growing offshore Chinese wealth in the financial hub, its chief executive said. The Singapore-headquartered firm, founded in 2014 in Beijing, currently employs 60 people in Hong Kong, where it started operations in late 2022, founder and CEO Tinahua Wu told Reuters late Monday. "Hong Kong is a very important global financial centre and it's not only about the several million local residents," Wu said. Tiger's parent firm UP Fintech Holding listed in the U.S. in 2019. "It is because it's backed by China," the 40-year-old former tech veteran said, adding growing accumulation of Chinese wealth offshore needs investment services. Securities trading activities have risen in the offshore Chinese market since Beijing started to unveil a slew of stimulus last September, a trend which has not been dampened by the global trade tensions, according to Wu. Mainland investors have poured HK$651 billion ($83 billion) into Hong Kong-listed shares via the Southbound Stock Connect so far this year, more than double the HK$283 billion during the same period last year, CICC analysts said in a note on Tuesday. The capital inflows augurs well for local brokerages closely connected to clients in China, the world's second-largest economy, at a time when U.S. President Donald Trump's trade war weighs on investor appetite for U.S. assets. The buoyant Hong Kong market has attracted some companies such as Chinese e-commerce giant Alibaba-affiliate Ant Group to foray into Hong Kong by acquiring a 50.55% stake in local broker Bright Smart in April. As more Chinese high-net worth individuals set up family offices in Hong Kong and domestic companies increasingly seek to expand offshore, Wu said Tiger expects sizable growth in demand from both individual and corporate clients. Tiger holds more than $50 billion worth of assets globally and operates in markets beyond Hong Kong, including the U.S., Australia, New Zealand, and Singapore. The brokerage's assets under custody, a key measure of client holdings in Tiger's Hong Kong accounts, quadrupled in the first quarter of 2025 from the same period last year, according to UP Fintech's first quarter report. Strong pipeline of initial public listings in Hong Kong with "star" Chinese firms coming to raise funds in the city has also resulted in heightened interest in buying and trading new shares, he said. ($1 = 7.8435 Hong Kong dollars) Sign in to access your portfolio
Business Insider
16 minutes ago
- Business Insider
Blueprint Medicines downgraded to Hold from Buy at TD Cowen
TD Cowen analyst Marc Frahm downgraded Blueprint Medicines (BPMC) to Hold from Buy with a $130 price target after Sanofi (SNY) announced its intention to acquire Blueprint for $9.1B in equity value and up to $9.5B including a contingent value right. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
33 minutes ago
- Yahoo
Asian Market: Discovering 3 Stocks That May Be Trading Below Their Estimated Value
As the Asian markets navigate through a period of economic recalibration amid global trade uncertainties and evolving inflation dynamics, investors are increasingly focused on identifying opportunities that may be trading below their intrinsic value. In this context, understanding what constitutes an undervalued stock is crucial—typically characterized by strong fundamentals and potential for growth that isn't fully reflected in their current market price. Name Current Price Fair Value (Est) Discount (Est) Xiamen Amoytop Biotech (SHSE:688278) CN¥77.25 CN¥153.79 49.8% Range Intelligent Computing Technology Group (SZSE:300442) CN¥42.93 CN¥85.11 49.6% RACCOON HOLDINGS (TSE:3031) ¥820.00 ¥1617.60 49.3% H.U. Group Holdings (TSE:4544) ¥3049.00 ¥6011.28 49.3% Shenzhen Yinghe Technology (SZSE:300457) CN¥17.25 CN¥34.44 49.9% cottaLTD (TSE:3359) ¥432.00 ¥853.28 49.4% Zhuhai CosMX Battery (SHSE:688772) CN¥13.52 CN¥27.01 49.9% Heartland Group Holdings (NZSE:HGH) NZ$0.79 NZ$1.58 49.9% Dive (TSE:151A) ¥919.00 ¥1819.21 49.5% China Kings Resources GroupLtd (SHSE:603505) CN¥21.43 CN¥42.38 49.4% Click here to see the full list of 307 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Overview: Innovent Biologics, Inc. is a biopharmaceutical company focused on the research and development of antibody and protein medicine products in China, the United States, and internationally, with a market cap of approximately HK$104.09 billion. Operations: Innovent Biologics generates revenue primarily from its biotechnology segment, amounting to CN¥9.42 billion. Estimated Discount To Fair Value: 42.1% Innovent Biologics is trading at HK$63.1, significantly below its estimated fair value of HK$109.06, suggesting it may be undervalued based on cash flows. With earnings expected to grow 41.08% annually and anticipated profitability within three years, the company shows promising financial prospects despite a forecasted low return on equity of 13.9%. Recent advancements in clinical trials for treatments like picankibart and mazdutide could enhance future revenue streams and market positioning in Asia's biopharma sector. Our earnings growth report unveils the potential for significant increases in Innovent Biologics' future results. Take a closer look at Innovent Biologics' balance sheet health here in our report. Overview: Eastroc Beverage(Group) Co., Ltd. focuses on the research, development, production, and sales of beverages in China with a market cap of CN¥166.40 billion. Operations: The company generates revenue of CN¥17.20 billion from the production, sales, and wholesale of beverages and pre-packaged foods in China. Estimated Discount To Fair Value: 17.1% Eastroc Beverage(Group) Co., Ltd. is trading at CNY 320, below its estimated fair value of CNY 386.2, highlighting potential undervaluation based on cash flows. The company reported strong earnings growth with net income reaching CNY 980.01 million in Q1 2025, up from CNY 663.88 million a year ago. Despite an unstable dividend track record, forecasted earnings and revenue growth outpace the Chinese market average, reflecting robust financial health and future prospects. Our comprehensive growth report raises the possibility that Eastroc Beverage(Group) is poised for substantial financial growth. Click here and access our complete balance sheet health report to understand the dynamics of Eastroc Beverage(Group). Overview: Fujikura Ltd. operates in the energy, telecommunications, electronics, automotive, and real estate sectors across Japan, the United States, China, and internationally with a market cap of approximately ¥1.88 trillion. Operations: Fujikura Ltd.'s revenue is derived from its operations in the energy, telecommunications, electronics, automotive, and real estate sectors across various international markets. Estimated Discount To Fair Value: 21.3% Fujikura Ltd. is trading at ¥6,808, significantly below its estimated fair value of ¥8,651.86, suggesting it may be undervalued based on cash flows. The company's earnings grew by 78.6% over the past year and are expected to continue outpacing the Japanese market with a forecasted annual growth of 10%. Despite a volatile share price and an unstable dividend track record, Fujikura's revenue growth prospects remain strong relative to market averages. In light of our recent growth report, it seems possible that Fujikura's financial performance will exceed current levels. Click to explore a detailed breakdown of our findings in Fujikura's balance sheet health report. Click here to access our complete index of 307 Undervalued Asian Stocks Based On Cash Flows. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1801 SHSE:605499 and TSE:5803. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
